Literature DB >> 7789022

Can MRI predict the histopathological response in patients with osteosarcoma after the first cycle of chemotherapy?

H C Holscher1, J L Bloem, H J van der Woude, J Hermans, M A Nooy, A H Taminiau, P C Hogendoorn.   

Abstract

The magnetic resonance (MR) changes after one cycle of chemotherapy were compared with the prechemotherapy studies in 39 patients with osteosarcoma, in order to identify MR changes which can be used to assess early response to chemotherapy. Measurements of total tumour volume, signal intensity, and tumour enhancement of the intra- and extraosseous tumour component were performed. Change in the amount of oedema was subjectively assessed. Changes observed were correlated with histopathological response. Changes in tumour volume and of the signal intensity of the extraosseous tumour component on T2-weighting were the only two parameters which correlated significantly (P < 0.05) with histopathological response. Increase of tumour volume is the most significant parameter and indicates poor response (sensitivity 89%, specificity 73%). Only one good responder showed increase of tumour volume. Decreased or stable tumour volume was observed in both good and poor responders. Increase of signal intensity was found exclusively in five poor responders (sensitivity 100%, specificity 23%). Decreased or stable signal intensity was observed in both good and poor responders. Changes in the amount of oedema and contrast enhancement could not predict response at an early stage. We conclude that increase of tumour volume and increase of T2 signal intensity of extraosseous tumour can be predictive for poor response. MR criteria are not helpful in the early identification of good responders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7789022     DOI: 10.1016/s0009-9260(05)83135-6

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  13 in total

1.  A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.

Authors:  Fariba Navid; Victor M Santana; Michael Neel; M Beth McCarville; Barry L Shulkin; Jianrong Wu; Catherine A Billups; Shenghua Mao; Vinay M Daryani; Clinton F Stewart; Michelle Kunkel; Wendene Smith; Deborah Ward; Alberto S Pappo; Armita Bahrami; David M Loeb; Jennifer Reikes Willert; Bhaskar N Rao; Najat C Daw
Journal:  Int J Cancer       Date:  2017-07-03       Impact factor: 7.396

2.  Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential ¹⁸F-FDG PET/CT and MRI.

Authors:  Byung Hyun Byun; Chang-Bae Kong; Ilhan Lim; Byung Il Kim; Chang Woon Choi; Won Seok Song; Wan Hyeong Cho; Dae-Geun Jeon; Jae-Soo Koh; Soo-Yong Lee; Sang Moo Lim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-21       Impact factor: 9.236

3.  Tumour response of osteosarcoma to neoadjuvant chemotherapy evaluated by magnetic resonance imaging as prognostic factor for outcome.

Authors:  Christoph J Laux; Gundula Berzaczy; Michael Weber; Susanna Lang; Martin Dominkus; Reinhard Windhager; Iris-Melanie Nöbauer-Huhmann; Philipp T Funovics
Journal:  Int Orthop       Date:  2014-11-30       Impact factor: 3.075

4.  Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma.

Authors:  Hendrik Pels; Annika Juergens; Isabell Schirgens; Axel Glasmacher; Holger Schulz; Andreas Engert; Gabriele Schackert; Heinz Reichmann; Frank Kroschinsky; Marlies Vogt-Schaden; Gerlinde Egerer; Udo Bode; Martina Deckert; Rolf Fimmers; Horst Urbach; Ingo G H Schmidt-Wolf; Uwe Schlegel
Journal:  Neuro Oncol       Date:  2010-02-16       Impact factor: 12.300

5.  Triple-phase contrast-enhanced MRI for the prediction of preoperative chemotherapeutic effect in patients with osteosarcoma: comparison with (99m)Tc-MIBI scintigraphy.

Authors:  Hiroshi Wakabayashi; Junko Saito; Junichi Taki; Nanako Hashimoto; Hiroyuki Tsuchiya; Toshifumi Gabata; Seigo Kinuya
Journal:  Skeletal Radiol       Date:  2015-09-18       Impact factor: 2.199

6.  Tumor volume change after chemotheraphy as a predictive factor of disease free survival for osteosarcoma.

Authors:  Seong-Hwan Moon; Kyoo-Ho Shin; Jin-Suck Suh; Woo-Ick Yang; Jae-Keong Noh; Soo-Bong Hahn
Journal:  Yonsei Med J       Date:  2005-02-28       Impact factor: 2.759

7.  Dynamic contrast-enhanced MR imaging for differentiation between enchondroma and chondrosarcoma.

Authors:  T De Coninck; L Jans; G Sys; W Huysse; T Verstraeten; R Forsyth; B Poffyn; K Verstraete
Journal:  Eur Radiol       Date:  2013-06-17       Impact factor: 5.315

Review 8.  The role of SPET and PET in monitoring tumour response to therapy.

Authors:  Chariklia Giannopoulou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-14       Impact factor: 9.236

9.  UK Guidelines for the Management of Bone Sarcomas.

Authors:  Robert Grimer; Nick Athanasou; Craig Gerrand; Ian Judson; Ian Lewis; Bruce Morland; David Peake; Beatrice Seddon; Jeremy Whelan
Journal:  Sarcoma       Date:  2010-12-29

10.  Evaluation of static and dynamic MRI for assessing response of bone sarcomas to preoperative chemotherapy: Correlation with histological necrosis.

Authors:  Priyadarshi Amit; Atul Malhotra; Rahul Kumar; Lokesh Kumar; Dilip Kumar Patro; Sundar Elangovan
Journal:  Indian J Radiol Imaging       Date:  2015 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.